Early PCSK9 inhibitor therapy significantly reduces the risk of major adverse cardiovascular events, including nonfatal myocardial infarction, cardiogenic death, stroke, hospitalization for recurrent ACS, and coronary revascularization. This evidence concerns the gene PCSK9 and Stroke.